| Attribute |
Value |
| Address1 |
399 Binney Street |
| Book Value |
-24.909 |
| City |
Cambridge |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
21.86 |
| Current Ratio |
2.713 |
| Custom Price Alert Confidence |
HIGH |
| Day High |
23.875 |
| Day Low |
20.8 |
| Debt To Equity |
45.872 |
| Ebitda |
-82,997,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-2.876 |
| Enterprise To Revenue |
16.641 |
| Enterprise Value |
238,671,760 |
| Esg Populated |
0 |
| Exchange |
NGM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Two Week High |
23.875 |
| Fifty Two Week High Change |
-2.0149994 |
| Fifty Two Week High Change Percent |
-0.08439788 |
| Fifty Two Week Low |
20.8 |
| Fifty Two Week Low Change |
1.0600014 |
| Fifty Two Week Low Change Percent |
0.050961606 |
| Fifty Two Week Range |
20.8 - 23.875 |
| Financial Currency |
USD |
| Full Exchange Name |
NasdaqGM |
| Full Time Employees |
75 |
| Fullday Change |
3.8600006 |
| Fullday Change Percent |
21.444448 |
| Fullday Price |
21.86 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-66,022,000 |
| Has Pre Post Market Data |
1 |
| Implied Shares Outstanding |
48,367,858 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,026-10-16 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts. |
| Long Name |
City Therapeutics, Inc. Common Stock |
| Market |
us_market |
| Market Cap |
1,057,321,344 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_1887698924 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-87,666,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Open |
23.0 |
| Operating Cashflow |
-77,671,000 |
| Operating Margins |
-8.041989 |
| Phone |
857 357 2024 |
| Previous Close |
18.0 |
| Price Hint |
2 |
| Price To Book |
-0.8775945 |
| Price To Sales Trailing12 Months |
73.72203 |
| Profit Margins |
0.0 |
| Quick Ratio |
2.698 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
3.8600006 |
| Regular Market Change Percent |
21.444448 |
| Regular Market Day High |
23.875 |
| Regular Market Day Low |
20.8 |
| Regular Market Day Range |
20.8 - 23.875 |
| Regular Market Open |
23.0 |
| Regular Market Previous Close |
18.0 |
| Regular Market Price |
21.86 |
| Regular Market Time |
1,792,170,878 |
| Regular Market Volume |
710,464 |
| Revenue Growth |
0.14 |
| Revenue Per Share |
2.572 |
| Sand P52 Week Change |
0.16207206 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
48,367,858 |
| Short Name |
City Therapeutics, Inc. Common Stock |
| Source Interval |
15 |
| State |
MA |
| Symbol |
CTY |
| Total Cash |
169,604,992 |
| Total Cash Per Share |
32.074 |
| Total Debt |
57,037,000 |
| Total Revenue |
14,342,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Type Disp |
Equity |
| Volume |
710,464 |
| Website |
https://www.citytx.com |
| Zip |
2,142 |